High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseHui Gao, Zongyao Wang, Chao Zhang et al.|Nature Medicine|2015Cited by 1.4k
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activitySauveur-Michel Maira, Carlos García-Echeverría, Frédéric Stauffer et al.|Molecular Cancer Therapeutics|2008Cited by 1.1k
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Saskia M. Brachmann, Edwige Lorthiois et al.|Cancer Discovery|2022Cited by 134